Anavex Life Sciences Corporation (NASDAQ:AVXL) currently has a daily average trading volume of 958.08K but it saw 1521948 shares traded in last market. With a market cap of 764.86M USD, the company’s current market price of $9.02 came rising about 6.43 while comparing to the previous closing price of $8.48. In past 52 weeks, the stock remained buoying in the range of price level as high as $10.45 and as low as $3.25. In the recent trading on the day, stock has struck highest price mark of $8.23 while lowest mark touched by it was $9.39.
Taking a look at 20-day trading activity of Anavex Life Sciences Corporation (AVXL) gives us an average price of $7.56, while its current price level is -13.68% below from 52-week high level whereas it is 177.54% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $6.32 while that of 200 days or SMA-200 reads an average of $5.28. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.55% during that period while stretching the period over a month that increases to 10.37%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 67.91 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Cantor Fitzgerald which downgraded the stock as “Neutral” in its note to investors issued on December 06, 2022, recommending a price target of between $16 and $11 for it. BTIG Research issued its recommendations for the stock as it initiated the price target for the stock is $35.
Over the week, AVXL’s stock price is moving 12.33% up while it is 67.35% when we observe its performance for the past one month. Year-to-date it is -3.11% down and over the past year, the stock is showing an upside performance of 34.23%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.12 beat the consensus estimate of -0.15 for the same. The company is expected to be releasing its next quarterly report in December, for which analysts forecasted an EPS of -0.17 while estimate for next year EPS is -0.55.
Currently, Anavex Life Sciences Corporation’s total number of outstanding shares is 84.80M with 3.05% of that held by the insiders while 32.06% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -31.98% and return on equity (ROE) at -30.03%. Stock’s beta reads 0.66. Stock has a price to book (P/B) ratio of 5.89. Its return on asset (ROA) is -27.74% on average.
